Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $3.7M | $2.7M | $3.5M | $1.9M | $1.1M | $1.1M | $262.9K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $8.5M | $3.7M | $2.7M | $3.5M | $1.9M | $1.1M | $1.1M | $262.9K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $19.5M | $9.7M | $7.1M | $6.5M | $5.0M | $3.6M | $1.7M | $691.1K |
| Operating income | −$23.1M | −$14.4M | −$10.8M | −$6.4M | −$5.6M | −$4.8M | −$2.4M | −$2.6M |
| EBITDA | −$16.8M | $1.8M | −$12.4M | −$2.6M | −$9.7M | −$3.6M | −$2.6M | −$2.4M |
| Net income | −$17.3M | $1.6M | −$12.6M | −$2.7M | −$9.7M | −$3.6M | −$2.6M | −$2.4M |
| Net margin | -203.4% | 44.0% | -466.6% | -75.6% | -498.2% | -317.3% | -237.7% | -912.2% |
| EPS (diluted) | -7.67 | 0.60 | -1.16 | -0.24 | -0.87 | -0.32 | -0.23 | -0.19 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CBLI.
No tracked institution reports a position in CBLI as of their last filing.
No one on the platform has traded CBLI yet.
| $226M |
| — |
| MACKMerrimack Pharmaceuticals, Inc. | $15.14 | +0.10% | $224M | — |
| SLRNAcelyrin, Inc. | $2.27 | +0.00% | $229M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.